Loading clinical trials...
Loading clinical trials...
A Multicenter, Open Label, Randomized, Balanced, Two Treatment, Three Period, Three Sequence, Reference Replicate Crossover, Single Dose, Bioequivalence Fed Study of Capecitabine Tablets in Comparison With XELODA in Adult Cancer Patients
Conditions
Interventions
Capecitabine
XELODA
Start Date
May 1, 2018
Primary Completion Date
October 1, 2018
Completion Date
November 1, 2018
Last Updated
February 19, 2018
NCT04704661
NCT05245812
NCT04550494
NCT05673200
NCT05372640
NCT07483307
Lead Sponsor
Qilu Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions